Wolin named director at Center for Carcinoid and Neuroendocrine Tumors at Mt. Sinai

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Edward Wolin was named director of the Mount Sinai Center for Carcinoid and Neuroendocrine Tumors.

The multidisciplinary center includes Mount Sinai specialists in gastroenterology, surgical oncology, hepatobiliary surgery, thoracic surgery, nuclear medicine, cardiology, medical oncology, radiology, pathology, endocrinology, and nutrition.

Wolin, who will also be a professor of medicine (hematology and medical oncology) at the Icahn School of Medicine at Mount Sinai, brings a robust research program that includes clinical trials aimed at finding the most effective treatments, including immunotherapy, biologic agents, targeted radiation therapy, and new approaches in molecular imaging for diagnosis.

He becomes the second director of the center which was founded by Richard Warner, professor of medicine (gastroenterology), a pioneer in neuroendocrine tumor research and treatment.

Wolin will lead the center along with Michelle Kang Kim, associate professor of medicine (gastroenterology), and who will serve as associate director after previously serving as interim director.

Wolin was most recently director of the Neuroendocrine Tumor Program at Montefiore Einstein Center for Cancer Care. He has pioneered innovative therapies with novel somatostatin analogs, mTOR inhibitors, anti-angiogenic drugs, and peptide receptor radiotherapy.

He was previously director of neuroendocrine tumor programs at the University of Kentucky Medical Center and Cedars-Sinai Medical Center in Los Angeles, where he founded and directed one of the then-largest carcinoid and neuroendocrine tumor programs in the country.

Wolin serves as co-medical director for the Carcinoid Cancer Foundation and on the Carcinoid Cancer Research Grants Scientific Review Committee for the American Association for Cancer Research.

YOU MAY BE INTERESTED IN

Secretary of the U.S. Department of Health and Human Services Robert F. Kennedy Jr. appeared before the House Energy and Commerce Subcommittee on Health to defend the HHS fiscal year 2026 budget proposal, and faced criticism from several Democratic lawmakers on what they described as a lack of transparency and scientific rigor in the agency’s recent decisions.

The full-scale Russian invasion of Ukraine has devastated the Ukrainian healthcare infrastructure, disrupting cancer care, halting clinical trials, and compounding long-standing systemic challenges.  Even before the war, Ukraine’s oncology system faced major constraints: Limited access to radiotherapy equipment, outdated chemotherapy supply chains, and workforce shortages. The invasion intensified these issues—cancer hospitals were damaged, warehouses destroyed,...

Patients affected by cancer are increasingly turning to artificial intelligence-powered chatbots, such as ChatGPT and Gemini, for answers to pressing health questions. These tools, available around the clock and free from geographic or scheduling constraints, are appealing when access to medical professionals is limited by financial, language, logistical, or emotional barriers. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login